Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Combination antiretroviral therapy (ART) has significantly reduced the morbidity and mortality resulting from HIV infection. ART is, however, unable to eradicate HIV, which persists latently in several cell types and tissues. Phylogenetic analyses suggested that the proliferation of cells infected before ART initiation is mainly responsible for residual viremia, although controversy still exists. Conversely, it is widely accepted that drug resistance mutations (DRMs) do not appear during ART in patients with suppressed viral loads. Studies based on sequence clustering have in fact indicated that, at least in developed countries, HIV-infected ART-naive patients are the major source of drug-resistant viruses. Analysis of longitudinally sampled sequences have also shown that DRMs have variable fitness costs, which are strongly influenced by the viral genetic background.

Original languageEnglish
Pages (from-to)24-32
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume48
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Phylogeny
Drug Resistance
HIV
Therapeutics
Mutation
Viremia
Viral Load
Developing Countries
HIV Infections
Cluster Analysis
Cell Proliferation
Viruses
Morbidity
Costs and Cost Analysis
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Phylogenies in ART : HIV reservoirs, HIV latency and drug resistance. / Bandera, Alessandra; Gori, Andrea; Clerici, Mario; Sironi, Manuela.

In: Current Opinion in Pharmacology, Vol. 48, 01.10.2019, p. 24-32.

Research output: Contribution to journalReview article

@article{3af01621134d40df95fb8a4cef10461a,
title = "Phylogenies in ART: HIV reservoirs, HIV latency and drug resistance",
abstract = "Combination antiretroviral therapy (ART) has significantly reduced the morbidity and mortality resulting from HIV infection. ART is, however, unable to eradicate HIV, which persists latently in several cell types and tissues. Phylogenetic analyses suggested that the proliferation of cells infected before ART initiation is mainly responsible for residual viremia, although controversy still exists. Conversely, it is widely accepted that drug resistance mutations (DRMs) do not appear during ART in patients with suppressed viral loads. Studies based on sequence clustering have in fact indicated that, at least in developed countries, HIV-infected ART-naive patients are the major source of drug-resistant viruses. Analysis of longitudinally sampled sequences have also shown that DRMs have variable fitness costs, which are strongly influenced by the viral genetic background.",
author = "Alessandra Bandera and Andrea Gori and Mario Clerici and Manuela Sironi",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.coph.2019.03.003",
language = "English",
volume = "48",
pages = "24--32",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Phylogenies in ART

T2 - HIV reservoirs, HIV latency and drug resistance

AU - Bandera, Alessandra

AU - Gori, Andrea

AU - Clerici, Mario

AU - Sironi, Manuela

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Combination antiretroviral therapy (ART) has significantly reduced the morbidity and mortality resulting from HIV infection. ART is, however, unable to eradicate HIV, which persists latently in several cell types and tissues. Phylogenetic analyses suggested that the proliferation of cells infected before ART initiation is mainly responsible for residual viremia, although controversy still exists. Conversely, it is widely accepted that drug resistance mutations (DRMs) do not appear during ART in patients with suppressed viral loads. Studies based on sequence clustering have in fact indicated that, at least in developed countries, HIV-infected ART-naive patients are the major source of drug-resistant viruses. Analysis of longitudinally sampled sequences have also shown that DRMs have variable fitness costs, which are strongly influenced by the viral genetic background.

AB - Combination antiretroviral therapy (ART) has significantly reduced the morbidity and mortality resulting from HIV infection. ART is, however, unable to eradicate HIV, which persists latently in several cell types and tissues. Phylogenetic analyses suggested that the proliferation of cells infected before ART initiation is mainly responsible for residual viremia, although controversy still exists. Conversely, it is widely accepted that drug resistance mutations (DRMs) do not appear during ART in patients with suppressed viral loads. Studies based on sequence clustering have in fact indicated that, at least in developed countries, HIV-infected ART-naive patients are the major source of drug-resistant viruses. Analysis of longitudinally sampled sequences have also shown that DRMs have variable fitness costs, which are strongly influenced by the viral genetic background.

UR - http://www.scopus.com/inward/record.url?scp=85064713830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064713830&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2019.03.003

DO - 10.1016/j.coph.2019.03.003

M3 - Review article

AN - SCOPUS:85064713830

VL - 48

SP - 24

EP - 32

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -